World-First Trial: PUMCH Proves New Drug Combination Nearly Doubles Response Rates in Aplastic Anemia
PUMCH's hematology team published the first-ever randomized trial showing luspatercept plus cyclosporine achieves 79% response rates in non-transfusion-dependent aplastic anemia — nearly double the standard treatment, especially in elderly patients.
A Drug Combination That Could Transform How We Treat Aplastic Anemia
Aplastic anemia — a condition where the bone marrow fails to produce enough blood cells — has limited treatment options, especially for patients who aren't severe enough to require blood transfusions but still suffer from chronic fatigue, bleeding risk, and infection vulnerability.
For decades, the standard treatment has been cyclosporine alone, an immunosuppressive drug that works in roughly half of patients. For those who don't respond, options are few.
Now, a landmark study from Peking Union Medical College Hospital (PUMCH) has demonstrated that adding luspatercept — a drug that stimulates red blood cell production — to standard cyclosporine therapy nearly doubles the early response rate.
The study, led by Dr. Han Bing (Chief Physician, Hematology), was published in BMC Medicine (Chinese Academy of Sciences Zone 1, IF 8.3) and represents the world's first prospective randomized controlled trial of this combination.
The Trial Results
The study enrolled 58 treatment-naïve patients with non-transfusion-dependent, non-severe aplastic anemia and randomized them to either luspatercept + cyclosporine or cyclosporine alone:
| Timepoint | Luspatercept + Cyclosporine | Cyclosporine Alone |
|---|---|---|
| 3-month response rate | 69.0% | 37.9% |
| 6-month response rate | 79.3% | 51.7% |
The benefit was even more pronounced in patients aged 60 and older — a population that traditionally responds poorly to immunosuppressive therapy and has the fewest treatment alternatives.
Why This Matters
Aplastic anemia affects approximately 2-5 per million people worldwide. While severe cases can be treated with bone marrow transplantation, many patients have non-severe disease that doesn't qualify for transplant but still significantly impairs quality of life.
For these patients — particularly elderly patients who cannot tolerate aggressive treatments — the luspatercept combination offers:
- Higher response rates — 79% vs. 52% at 6 months
- Faster responses — Significant improvement visible at just 3 months
- Better tolerability — Luspatercept has a favorable side effect profile
- Avoidance of transfusion dependence — Treating effectively before patients deteriorate
Hematology Treatment Cost: China vs Western Countries
| Treatment | China (PUMCH) | United States |
|---|---|---|
| Cyclosporine therapy (annual) | $1,500 - $4,000 | $8,000 - $20,000 |
| Luspatercept (per month) | $1,000 - $2,500 | $5,000 - $12,000 |
| Bone marrow transplant | $30,000 - $60,000 | $200,000 - $500,000 |
| ATG immunosuppressive therapy | $8,000 - $15,000 | $40,000 - $80,000 |
China prices include medications, monitoring, hospital visits, and laboratory tests.
About PUMCH Hematology
- Ranked #1 hospital in China for 14 consecutive years
- Hematology department with extensive experience in aplastic anemia, MDS, and bone marrow failure syndromes
- First to conduct this world-first randomized controlled trial for luspatercept in aplastic anemia
- Located in central Beijing
Frequently Asked Questions
Is luspatercept available for international patients at PUMCH?
Luspatercept is approved in China and available at PUMCH for eligible patients. International patients can access this treatment through PUMCH's hematology department after a comprehensive evaluation. SinomedTrip can coordinate the initial consultation and help determine whether you qualify for this therapy.
How long would I need to stay in China for aplastic anemia treatment?
The initial evaluation and treatment initiation typically requires 2 to 4 weeks in Beijing. Luspatercept is administered as a subcutaneous injection every three weeks, so some patients choose to stay for multiple cycles. Alternatively, after the initial cycles at PUMCH, your local hematologist can continue the treatment at home with remote guidance from the PUMCH team.
What are the side effects of luspatercept compared to standard aplastic anemia treatments?
Luspatercept generally has a favorable side effect profile compared to aggressive immunosuppression. Common side effects include fatigue, headache, and mild bone pain, which are usually manageable. Unlike ATG therapy, luspatercept does not carry the risk of severe allergic reactions or profound immunosuppression, making it particularly suitable for elderly patients.
Can my local hematologist collaborate with the PUMCH team during my treatment?
Yes. PUMCH encourages collaborative care with your home physician. After the initial evaluation and treatment cycles in Beijing, the PUMCH team can provide detailed treatment protocols and communicate directly with your local hematologist to ensure continuity of care. SinomedTrip can facilitate these communications including translation if needed.
Living with aplastic anemia or a bone marrow failure syndrome? Request a free hematology consultation →
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
